Literature DB >> 15671266

A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo.

Dong-Hyun Hong1, Basil S Pawlyk, Michael Adamian, Michael A Sandberg, Tiansen Li.   

Abstract

PURPOSE: The retinitis pigmentosa GTPase regulator (RPGR) is essential for the maintenance of photoreceptor viability. RPGR is expressed as constitutive and ORF15 variants because of alternative splicing. This study was designed to examine whether the retina-specific ORF15 variant alone could substantially substitute for RPGR function. A further objective was to test whether the highly repetitive purine-rich region of ORF15 could be abbreviated without ablating the function, so as to accommodate RPGR replacement genes in adenoassociated virus (AAV) vectors.
METHODS: A cDNA representing RPGR-ORF15 but shortened by 654 bp in the repetitive region was placed under the control of a chicken beta-actin (CBA) hybrid promoter. The resultant construct was transfected into mouse embryonic stem cells. Clones expressing the transgene were selected and injected into mouse blastocysts. Transgenic chimeras were crossed with RPGR knockout (KO) mice. Mice expressing the transgene but null for endogenous RPGR (Tg/KO) were studied from 1 month to 18 months of age by light and electron microscopy, immunofluorescence, and electroretinography (ERG). The results were compared with those of wild-type (WT) and RPGR-null control mice.
RESULTS: Transgenic RPGR-ORF15 was found in the connecting cilia of rod and cone photoreceptors, at approximately 20% of the WT level. Photoreceptor morphology, cone opsin localization, expression of GFAP (a marker for retinal degeneration) and ERGs were consistent with the transgene exerting substantial rescue of retinal degeneration due to loss of endogenous RPGR.
CONCLUSIONS: RPGR-ORF15 is the functionally significant variant in photoreceptors. The length of its repetitive region can be reduced while preserving its function. The current findings should facilitate the design of gene replacement therapy for RPGR-null mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671266     DOI: 10.1167/iovs.04-1065

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  36 in total

1.  Transcriptional profile analysis of RPGRORF15 frameshift mutation identifies novel genes associated with retinal degeneration.

Authors:  Sem Genini; Barbara Zangerl; Julianna Slavik; Gregory M Acland; William A Beltran; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

2.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

Review 3.  Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms.

Authors:  Paulo A Ferreira
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

4.  Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization.

Authors:  Kyoungmin Park; Ji Jin; Yang Hu; Kevin Zhou; Jian-xing Ma
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

5.  Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP.

Authors:  Qihong Zhang; Joseph C Giacalone; Charles Searby; Edwin M Stone; Budd A Tucker; Val C Sheffield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-08       Impact factor: 11.205

6.  Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations.

Authors:  Xun Sun; James H Park; Jessica Gumerson; Zhijian Wu; Anand Swaroop; Haohua Qian; Antonina Roll-Mecak; Tiansen Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

7.  Localizing the RPGR protein along the cilium: a new method to determine efficacies to treat RPGR mutations.

Authors:  R Da Costa; E Glaus; A Tiwari; B Kloeckener-Gruissem; W Berger; J Neidhardt
Journal:  Gene Ther       Date:  2015-01-29       Impact factor: 5.250

8.  RPGR-associated retinal degeneration in human X-linked RP and a murine model.

Authors:  Wei Chieh Huang; Alan F Wright; Alejandro J Roman; Artur V Cideciyan; Forbes D Manson; Dina Y Gewaily; Sharon B Schwartz; Sam Sadigh; Maria P Limberis; Peter Bell; James M Wilson; Anand Swaroop; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-15       Impact factor: 4.799

Review 9.  Gene augmentation for X-linked retinitis pigmentosa caused by mutations in RPGR.

Authors:  William A Beltran; Artur V Cideciyan; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

10.  Development of a Molecularly Stable Gene Therapy Vector for the Treatment of RPGR-Associated X-Linked Retinitis Pigmentosa.

Authors:  Joseph C Giacalone; Jeaneen L Andorf; Qihong Zhang; Erin R Burnight; Dalyz Ochoa; Austin J Reutzel; Malia M Collins; Val C Sheffield; Robert F Mullins; Ian C Han; Edwin M Stone; Budd A Tucker
Journal:  Hum Gene Ther       Date:  2019-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.